ResMed Inc. (RMD) 10-Year Financial Performance & Capital Metrics

RMD • • Industrial / General

HealthcareMedical InstrumentsWound Care & Therapeutic DevicesSpecialized Therapeutic Devices

AboutResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.Show more

Revenue $5.15B +9.8%
EBITDA $1.92B +25.1%
Net Income $1.4B +37.2%
EPS (Diluted) 9.51 +37.4%
Gross Margin 59.36% +4.7%
EBITDA Margin 37.33% +13.9%
Operating Margin 32.75% +16.3%
Net Margin 27.22% +24.9%
ROE 25.86% +13.9%
ROIC 22.75% +26.2%
Debt/Equity 0.14 -20.6%
Interest Coverage 133.66 +362.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 24.2%
✓Strong 5Y profit CAGR of 17.6%
✓Strong Piotroski F-Score: 8/9
✓FCF machine: 32.3% free cash flow margin
✓14 consecutive years of dividend growth
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y11.85%

5Y11.72%

3Y12.88%

TTM9.36%

Profit (Net Income) CAGR

10Y14.78%

5Y17.64%

3Y21.58%

TTM29.21%

EPS CAGR

10Y14.43%

5Y17.37%

3Y21.52%

TTM29.4%

ROCE

10Y Avg21.04%

5Y Avg23.41%

3Y Avg23.18%

Latest25.7%

Peer Comparison

Specialized Therapeutic Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RMDResMed Inc.	38.05B	260.70	27.41	9.84%	27.35%	23.49%	4.37%	0.14
ZJYLJin Medical International Ltd.	22.54M	0.14	6.13	18.57%	10.94%	16.93%		0.41
FEMYFemasys Inc.	38.2M	0.64	-0.76	51.97%	-9.61%	-434.6%		3.23
NYXHNyxoah S.A.	221.59M	5.15	-2.85	3.98%	-14.85%	-164.31%		0.20
MLSSMilestone Scientific Inc.	22.8M	0.29	-4.91	-12.19%	-76.78%	-208.8%		0.06
NVCRNovoCure Limited	1.55B	13.80	-8.85	18.82%	-27.66%	-52.05%		1.90
EKSOEkso Bionics Holdings, Inc.	22.43M	8.55	-15.27	-1.94%	-70.74%	-107.8%		0.47
PLSEPulse Biosciences, Inc.	955.52M	14.10	-15.33		-868.99%	-80.62%		0.08

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	1.84B	2.07B	2.34B	2.61B	2.96B	3.2B	3.58B	4.22B	4.69B	5.15B
Revenue Growth %	0.1%	0.12%	0.13%	0.11%	0.13%	0.08%	0.12%	0.18%	0.11%	0.1%
Cost of Goods Sold+	772.22M	864.99M	978.03M	1.07B	1.24B	1.36B	1.55B	1.87B	2.03B	2.09B
COGS % of Revenue	0.42%	0.42%	0.42%	0.41%	0.42%	0.42%	0.43%	0.44%	0.43%	0.41%
Gross Profit+	1.07B	1.2B	1.36B	1.54B	1.72B	1.84B	2.02B	2.36B	2.66B	3.05B
Gross Margin %	0.58%	0.58%	0.58%	0.59%	0.58%	0.58%	0.57%	0.56%	0.57%	0.59%
Gross Profit Growth %	0.05%	0.13%	0.13%	0.13%	0.12%	0.07%	0.1%	0.16%	0.13%	0.15%
Operating Expenses+	637.54M	775.95M	820.33M	957.32M	908.73M	935.42M	1.02B	1.22B	1.34B	1.37B
OpEx % of Revenue	0.35%	0.38%	0.35%	0.37%	0.31%	0.29%	0.29%	0.29%	0.29%	0.27%
Selling, General & Admin	488.06M	553.97M	600.37M	645.01M	676.69M	670.39M	739.37M	874M	917.14M	991.02M
SG&A % of Revenue	0.27%	0.27%	0.26%	0.25%	0.23%	0.21%	0.21%	0.21%	0.2%	0.19%
Research & Development	118.65M	144.47M	155.15M	180.65M	201.95M	225.28M	253.57M	287.64M	307.52M	331.28M
R&D % of Revenue	0.06%	0.07%	0.07%	0.07%	0.07%	0.07%	0.07%	0.07%	0.07%	0.06%
Other Operating Expenses	30.84M	77.51M	64.81M	131.66M	30.09M	39.75M	31.08M	62.15M	110.75M	47.3M
Operating Income+	428.95M	425.8M	541.83M	579.26M	809.66M	903.68M	1B	1.13B	1.32B	1.69B
Operating Margin %	0.23%	0.21%	0.23%	0.22%	0.27%	0.28%	0.28%	0.27%	0.28%	0.33%
Operating Income Growth %	0.05%	-0.01%	0.27%	0.07%	0.4%	0.12%	0.11%	0.13%	0.17%	0.28%
EBITDA+	515.8M	537.96M	661.79M	730.06M	991.03M	1.1B	1.19B	1.33B	1.54B	1.92B
EBITDA Margin %	0.28%	0.26%	0.28%	0.28%	0.34%	0.34%	0.33%	0.31%	0.33%	0.37%
EBITDA Growth %	0.07%	0.04%	0.23%	0.1%	0.36%	0.11%	0.09%	0.11%	0.16%	0.25%
D&A (Non-Cash Add-back)	86.85M	112.16M	119.96M	150.79M	181.37M	191.52M	193.84M	196.52M	216.21M	235.81M
EBIT	435.87M	456.73M	560.26M	555M	809.06M	912.35M	982.79M	1.16B	1.31B	1.68B
Net Interest Income+	5.65M	-11.15M	-11.98M	-33.86M	-39.36M	-23.63M	-22.31M	-47.38M	-45.71M	-12.61M
Interest Income	16.86M	17.09M	16.38M	2.3M	1.02M	362K	0	0	0	0
Interest Expense	11.21M	28.24M	28.36M	36.16M	40.38M	23.99M	22.31M	47.38M	45.71M	12.61M
Other Income/Expense	10.61M	-7.05M	-20.52M	-60.42M	-76.57M	-20.02M	-39.8M	-30.21M	-55.09M	-7.8M
Pretax Income+	439.56M	418.74M	521.31M	518.85M	733.09M	883.66M	960.48M	1.1B	1.26B	1.68B
Pretax Margin %	0.24%	0.2%	0.22%	0.2%	0.25%	0.28%	0.27%	0.26%	0.27%	0.33%
Income Tax+	87.16M	76.46M	205.72M	114.25M	111.41M	409.16M	181.05M	204.11M	243.85M	276.84M
Effective Tax Rate %	0.8%	0.82%	0.61%	0.78%	0.85%	0.54%	0.81%	0.81%	0.81%	0.83%
Net Income+	352.41M	342.28M	315.59M	404.59M	621.67M	474.5M	779.44M	897.56M	1.02B	1.4B
Net Margin %	0.19%	0.17%	0.13%	0.16%	0.21%	0.15%	0.22%	0.21%	0.22%	0.27%
Net Income Growth %	-0%	-0.03%	-0.08%	0.28%	0.54%	-0.24%	0.64%	0.15%	0.14%	0.37%
Net Income (Continuing)	352.41M	342.28M	315.59M	404.59M	621.67M	474.5M	779.44M	897.56M	1.02B	1.4B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	2.49	2.40	2.19	2.80	4.27	3.24	5.30	6.09	6.92	9.51
EPS Growth %	0.01%	-0.04%	-0.09%	0.28%	0.53%	-0.24%	0.64%	0.15%	0.14%	0.37%
EPS (Basic)	2.51	2.42	2.21	2.83	4.31	3.27	5.34	6.12	6.94	9.55
Diluted Shares Outstanding	141.67M	142.45M	143.99M	144.48M	145.65M	146.45M	147.04M	147.46M	147.55M	147.34M
Basic Shares Outstanding	140.24M	141.36M	142.76M	143.11M	144.34M	145.31M	146.07M	146.76M	147.02M	146.72M
Dividend Payout Ratio	0.48%	0.54%	0.63%	0.52%	0.36%	0.48%	0.31%	0.29%	0.28%	0.22%

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	1.42B	1.64B	1.07B	1.15B	1.52B	1.57B	1.93B	2.37B	2.36B	3.51B
Cash & Short-Term Investments	731.43M	821.93M	188.7M	147.13M	463.16M	295.28M	273.71M	227.89M	238.36M	1.21B
Cash Only	731.43M	821.93M	188.7M	147.13M	463.16M	295.28M	273.71M	227.89M	238.36M	1.21B
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	382.09M	450.53M	483.68M	528.48M	474.64M	614.29M	575.95M	704.91M	837.27M	990.67M
Days Sales Outstanding	75.85	79.57	75.44	74	58.59	70.14	58.75	60.93	65.23	70.26
Inventory	224.46M	268.32M	268.7M	349.64M	416.92M	457.03M	743.91M	998.01M	822.25M	927.71M
Days Inventory Outstanding	106.09	113.22	100.28	119.27	122.8	122.87	174.75	195.08	147.84	161.91
Other Current Assets	0	0	0	0	75.26M	0	131.26M	179.93M	180.01M	164.5M
Total Non-Current Assets+	1.84B	1.82B	2B	2.96B	3.06B	3.15B	3.16B	4.38B	4.51B	4.67B
Property, Plant & Equipment	384.28M	394.24M	386.55M	387.46M	535.68M	592.07M	630.5M	665.81M	699.15M	718.29M
Fixed Asset Turnover	4.78x	5.24x	6.05x	6.73x	5.52x	5.40x	5.68x	6.34x	6.70x	7.16x
Goodwill	1.06B	1.06B	1.07B	1.86B	1.89B	1.93B	1.94B	2.77B	2.84B	3.05B
Intangible Assets	299.81M	261.8M	215.18M	521.95M	448.17M	392.58M	345.94M	552.34M	485.9M	464.86M
Long-Term Investments	33.81M	38.32M	41.23M	56.7M	51.1M	75.45M	67.22M	156.89M	169.77M	85.03M
Other Non-Current Assets	6.58M	3.74M	232.48M	94.28M	97.58M	85.46M	104.53M	105.56M	114.23M	100.81M
Total Assets+	3.26B	3.47B	3.06B	4.11B	4.59B	4.73B	5.1B	6.75B	6.87B	8.17B
Asset Turnover	0.56x	0.60x	0.76x	0.63x	0.64x	0.68x	0.70x	0.63x	0.68x	0.63x
Asset Growth %	0.49%	0.06%	-0.12%	0.34%	0.12%	0.03%	0.08%	0.32%	0.02%	0.19%
Total Current Liabilities+	637.99M	360.13M	511.25M	555.99M	602.76M	911.77M	689.3M	758.53M	910.65M	1.02B
Accounts Payable	92.57M	92.76M	92.72M	115.72M	135.79M	138.01M	159.25M	150.76M	237.73M	278.16M
Days Payables Outstanding	43.76	39.14	34.6	39.48	39.99	37.1	37.41	29.47	42.74	48.55
Short-Term Debt	299.44M	0	11.47M	11.99M	11.99M	12M	9.92M	9.9M	9.9M	9.9M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	243K	460K	2.37M	244K	0	0	1.95M	9.56M	4.65M	2.69M
Current Ratio	2.23x	4.57x	2.08x	2.06x	2.53x	1.73x	2.80x	3.12x	2.59x	3.44x
Quick Ratio	1.87x	3.82x	1.56x	1.43x	1.84x	1.23x	1.72x	1.81x	1.69x	2.53x
Cash Conversion Cycle	138.18	153.65	141.11	153.8	141.39	155.9	196.09	226.54	170.33	183.63
Total Non-Current Liabilities+	923.88M	1.15B	493.69M	1.48B	1.49B	930.68M	1.05B	1.86B	1.1B	1.19B
Long-Term Debt	873.33M	1.08B	269.99M	1.26B	1.16B	643.35M	765.33M	1.43B	697.31M	658.39M
Capital Lease Obligations	0	0	0	0	101.88M	114.78M	120.45M	116.85M	141.44M	153.01M
Deferred Tax Liabilities	9.06M	13.82M	13.08M	11.38M	13.01M	11.32M	9.71M	90.65M	79.34M	77.68M
Other Non-Current Liabilities	1.21M	2.43M	139.03M	128.11M	121.26M	69.73M	54.86M	105.35M	42.26M	141.52M
Total Liabilities	1.56B	1.51B	1B	2.04B	2.09B	1.84B	1.74B	2.62B	2.01B	2.21B
Total Debt+	1.17B	1.08B	281.45M	1.27B	1.3B	793.72M	917.55M	1.58B	873.93M	851.81M
Net Debt	441.34M	256.68M	92.75M	1.12B	836.11M	498.44M	643.84M	1.35B	635.57M	-357.64M
Debt / Equity	0.69x	0.55x	0.14x	0.61x	0.52x	0.28x	0.27x	0.38x	0.18x	0.14x
Debt / EBITDA	2.27x	2.01x	0.43x	1.74x	1.31x	0.72x	0.77x	1.19x	0.57x	0.44x
Net Debt / EBITDA	0.86x	0.48x	0.14x	1.54x	0.84x	0.46x	0.54x	1.02x	0.41x	-0.19x
Interest Coverage	38.28x	15.08x	19.11x	16.02x	20.05x	37.67x	44.83x	23.89x	28.88x	133.66x
Total Equity+	1.69B	1.96B	2.06B	2.07B	2.5B	2.89B	3.36B	4.13B	4.86B	5.97B
Equity Growth %	0.07%	0.16%	0.05%	0.01%	0.21%	0.16%	0.16%	0.23%	0.18%	0.23%
Book Value per Share	11.96	13.76	14.30	14.34	17.14	19.70	22.86	28.01	32.97	40.50
Total Shareholders' Equity	1.69B	1.96B	2.06B	2.07B	2.5B	2.89B	3.36B	4.13B	4.86B	5.97B
Common Stock	563K	569K	571K	575K	580K	583K	586K	588K	588K	761K
Retained Earnings	2.16B	2.32B	2.43B	2.44B	2.83B	3.08B	3.61B	4.25B	4.99B	6.08B
Treasury Stock	-1.55B	-1.55B	-1.6B	-1.62B	-1.62B	-1.62B	-1.62B	-1.62B	-1.77B	-2.07B
Accumulated OCI	-222.66M	-189.06M	-224.33M	-253.01M	-283.98M	-193.49M	-312.75M	-272.53M	-251.53M	-74.7M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	547.93M	414.05M	505.03M	459.05M	802.25M	736.72M	351.15M	693.3M	1.4B	1.75B
Operating CF Margin %	0.3%	0.2%	0.22%	0.18%	0.27%	0.23%	0.1%	0.16%	0.3%	0.34%
Operating CF Growth %	0.43%	-0.24%	0.22%	-0.09%	0.75%	-0.08%	-0.52%	0.97%	1.02%	0.25%
Net Income	352.41M	342.28M	315.59M	404.59M	621.67M	474.5M	779.44M	897.56M	1.02B	1.4B
Depreciation & Amortization	86.85M	112.16M	119.96M	150.79M	181.37M	191.52M	193.84M	197.56M	216.21M	235.81M
Stock-Based Compensation	46.41M	45.92M	48.41M	52.07M	57.56M	63.93M	65.26M	71.14M	80.18M	91.66M
Deferred Taxes	3.56M	1.96M	11.59M	28.93M	39.58M	-3.31M	0	216K	0	0
Other Non-Cash Items	-2.99M	1.62M	411K	-286K	-7K	8.67M	20.69M	-11.05M	161.2M	6.66M
Working Capital Changes	61.69M	-89.88M	9.06M	-177.05M	-97.92M	1.41M	-708.08M	-462.13M	-77.29M	16.74M
Change in Receivables	-27.31M	-63.6M	-32.36M	-18.01M	54.38M	-129.19M	19.35M	-106.51M	-134.28M	-76.68M
Change in Inventory	30.49M	-41.6M	1.49M	-84.19M	-69.88M	-21.95M	-311.68M	-248.83M	172.2M	-80.17M
Change in Payables	46.38M	34.58M	200.65M	-27.28M	-23.42M	210.71M	-247.63M	31.34M	0	90.96M
Cash from Investing+	-1.13B	-81.89M	-101.82M	-1.08B	-179.86M	-158.46M	-229.92M	-1.16B	-269.78M	-200.04M
Capital Expenditures	-67.83M	-71.48M	-71.46M	-77.34M	-105.94M	-116.83M	-156.04M	-134M	-99.46M	-89.86M
CapEx % of Revenue	0.04%	0.03%	0.03%	0.03%	0.04%	0.04%	0.04%	0.03%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-468K	3.32M	8.97M	-8.63M	-10.61M	19.22M	-17.18M	15.2M	-15.4M	35.48M
Cash from Financing+	612.58M	-262.87M	-1.03B	580.64M	-317.29M	-764.63M	-128.36M	422.87M	-1.12B	-606.25M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-168.13M	-186.35M	-199.5M	-211.71M	-225.09M	-226.71M	-245.34M	-258.28M	-282.32M	-310.88M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.23M	-19.84M	38.23M	-29.01M	-46.36M	-53.71M	-52.41M	-32.99M	-10.05M	-29.79M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	480.1M	342.58M	433.57M	381.71M	696.32M	619.89M	195.11M	559.3M	1.29B	1.66B
FCF Margin %	0.26%	0.17%	0.19%	0.15%	0.24%	0.19%	0.05%	0.13%	0.27%	0.32%
FCF Growth %	0.54%	-0.29%	0.27%	-0.12%	0.82%	-0.11%	-0.69%	1.87%	1.3%	0.29%
FCF per Share	3.39	2.40	3.01	2.64	4.78	4.23	1.33	3.79	8.72	11.28
FCF Conversion (FCF/Net Income)	1.55x	1.21x	1.60x	1.13x	1.29x	1.55x	0.45x	0.77x	1.37x	1.25x
Interest Paid	11.21M	28.24M	28.36M	36.16M	40.38M	23.99M	22.31M	47.38M	45.71M	28.41M
Taxes Paid	68.97M	92.9M	170.65M	242.86M	180.36M	221.36M	478.12M	216.87M	278.4M	214.01M

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	21.47%	18.73%	15.7%	19.59%	27.21%	17.63%	24.96%	23.96%	22.7%	25.86%
Return on Invested Capital (ROIC)	19.46%	14.67%	18.6%	16.25%	18.6%	20.18%	20.31%	17.9%	18.03%	22.75%
Gross Margin	58%	58.15%	58.21%	58.95%	58.09%	57.53%	56.57%	55.78%	56.67%	59.36%
Net Margin	19.17%	16.56%	13.49%	15.52%	21.02%	14.84%	21.78%	21.25%	21.79%	27.22%
Debt / Equity	0.69x	0.55x	0.14x	0.61x	0.52x	0.28x	0.27x	0.38x	0.18x	0.14x
Interest Coverage	38.28x	15.08x	19.11x	16.02x	20.05x	37.67x	44.83x	23.89x	28.88x	133.66x
FCF Conversion	1.55x	1.21x	1.60x	1.13x	1.29x	1.55x	0.45x	0.77x	1.37x	1.25x
Revenue Growth	9.52%	12.4%	13.23%	11.38%	13.44%	8.11%	11.93%	18.02%	10.95%	9.84%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Sleep And Respiratory	-	-	-	-	-	-	2.82B	3.18B	3.73B	4.1B
Sleep And Respiratory Growth	-	-	-	-	-	-	-	12.54%	17.24%	10.10%
Software As Service	-	-	-	-	275.8M	354.63M	373.59M	400.83M	497.98M	584.13M
Software As Service Growth	-	-	-	-	-	28.58%	5.35%	7.29%	24.24%	17.30%
Devices And Masks	-	-	-	-	2.33B	2.6B	-	-	-	-
Devices And Masks Growth	-	-	-	-	-	11.65%	-	-	-	-
Devices	-	-	1.16B	1.3B	-	-	-	-	-	-
Devices Growth	-	-	-	12.28%	-	-	-	-	-	-
Mask Systems Motors And Other Accessories	703M	745.6M	767.7M	879.6M	-	-	-	-	-	-
Mask Systems Motors And Other Accessories Growth	-	6.06%	2.96%	14.58%	-	-	-	-	-	-
Flow Generators	975.9M	1.06B	-	-	-	-	-	-	-	-
Flow Generators Growth	-	9.05%	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
U [S]	-	-	1.23B	1.35B	-	-	-	-	-	2.98B
U [S] Growth	-	-	-	9.44%	-	-	-	-	-	-
Global	344.29M	408.18M	684.26M	994.98M	2.61B	2.96B	-	3.58B	-	1.71B
Global Growth	-	18.56%	67.64%	45.41%	161.97%	13.44%	-	-	-	-
Sleep And Respiratory	-	-	-	-	-	-	-	-	3.73B	-
Sleep And Respiratory Growth	-	-	-	-	-	-	-	-	-	-
Software As Service	-	-	-	-	-	-	-	-	497.98M	-
Software As Service Growth	-	-	-	-	-	-	-	-	-	-
Us Canada And Latin America	962.7M	1.13B	-	-	1.7B	-	-	-	-	-
Us Canada And Latin America Growth	-	17.42%	-	-	-	-	-	-	-	-
D [E]	184.25M	163.26M	153.28M	-	-	-	-	-	-	-
D [E] Growth	-	-11.39%	-6.11%	-	-	-	-	-	-	-
F [R]	145.5M	136.85M	-	-	-	-	-	-	-	-
F [R] Growth	-	-5.95%	-	-	-	-	-	-	-	-
A [U]	42.17M	-	-	-	-	-	-	-	-	-
A [U] Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

ResMed Inc. (RMD) has a price-to-earnings (P/E) ratio of 27.4x. This suggests investors expect higher future growth.

Growth & Financials

ResMed Inc. (RMD) reported $5.26B in revenue for fiscal year 2025. This represents a 284% increase from $1.37B in 2012.

ResMed Inc. (RMD) grew revenue by 9.8% over the past year. This is steady growth.

Yes, ResMed Inc. (RMD) is profitable, generating $1.44B in net income for fiscal year 2025 (27.2% net margin).

Dividend & Returns

Yes, ResMed Inc. (RMD) pays a dividend with a yield of 0.81%. This makes it attractive for income-focused investors.

ResMed Inc. (RMD) has a return on equity (ROE) of 25.9%. This is excellent, indicating efficient use of shareholder capital.

ResMed Inc. (RMD) generated $1.77B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...